News Archive

Rapydan gains approval of Swedish Medical Authority

26 January 2007.
The Swedish Medical Products Authority grants marketing authorisation for Rapydan®, an advanced topical anaesthetic plaster.

Management of pain associated with venous access and canulation is becoming increasingly important, especially in the management of paediatric patients.

Rapydan® medicated plasters combine two effective and fast acting local anaesthetic agents, lidocaine and tetracaine, with an advanced heating component to accelerate the time to a pain free procedure. The patented controlled heat assisted drug delivery (CHADD ®) technology within the Rapydan® medicated plaster makes Rapydan® faster than conventional anaesthetic creams and plasters, supporting nursing staff and clinicians in the delivery of efficient pain free procedures.

Following the approval by the Swedish authorities Rapydan® is now entering the Mutual Recognition process with the aim of achieving pan-European marketing authorisation during the summer of 2007.

Rapydan® is licensed in Sweden from the age of three years and above.

Download PDF
of transcript (76KB)